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Wenfeng Kang1,2, Robert S DiPaola2 and Alexei Vazquez1*Abstract
Background: Drug interactions can have a significant impact on the response to combinatorial therapy for
anticancer treatment. In some instances these interactions can be anticipated based on pre-clinical models.
However, the anticipation of drug interactions in the clinical context is in general a challenging task.
Methods: Here we propose the pooled analysis of clinical trials as a mean to investigate drug interactions in
anticancer therapy. To this end we collected 1,163 Phase II clinical trials with response data on over 53,745 subjects.
Results: We provide statistical definitions of drugs resulting in clinical synergy and antagonism and identify drug
combinations in each group. We also quantify the possibility of inferring interactions between three or more drugs
from parameters characterizing the action of single and two-drugs combinations.
Conclusions: Our analysis provides a statistical methodology to track the performance of drug combinations in
anticancer therapy and to quantify drug interactions in the clinical context.
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Systems biologyBackground
Given the low rate of phase III trials success,
complimentary options to optimize earlier trial develop-
ment, especially with combination therapy, would be critic-
ally important [1]. The identification of effective drug
combinations is, however, a challenging task [2], given the
large number of potential targets and agents available or
under investigation. For example, 100 FDA approved drugs
would result in about 5,000 two-drug combinations, and
the number increases exponentially if we consider combi-
nations of multiple agents. Additionally, preclinical drug
combination screens explore various concentration ranges
for each drug in a combination, making the exhaustive
screen of all possible drug combinations difficult. Although
preclinical studies historically have helped inform early trial
development of combination therapies, the contributory
value of phase II trials and ultimate success in identifying* Correspondence: vazqueal@umdnj.edu
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reproduction in any medium, provided the oragents with a survival impact in phase III trials has been
reported to be low, warranting new methodologies [3].
Meta-analyses pooling together many clinical trials have
been used to better quantify the performance of a new an-
ticancer treatment (single agents or combinations) relative
to a standard treatment [4-7]. We hypothesized that data
analyzed across large numbers of clinical trials could also
be utilized to obtain an estimate of the interaction be-
tween anticancer drugs. Several drug combinations have
been tested in clinical trials in the past years, providing a
unique resource to understand the response patterns of
drug combinations. A typical measure for treatment suc-
cess is the clinical overall response rate (ORR), defined as
the percentage of patients whose cancer shrinks (partial
response) or disappears (complete response) after treat-
ment. By observing successful, and unsuccessful, combina-
tions defined by ORR in multiple cancer types we
hypothesized that we could identify synergistic drug com-
binations with a response rate higher than what is
expected. In addition to increased response rate, we hy-
pothesized that we could identify drug interactions withd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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to drugs are caused by interactions between drugs [8],
underscoring the need to identify antagonistic drug inter-
actions as well.
Although theoretical foundations for the experimental
design to in vitro study drug combinations are well
established [9], methodologies to assess large and varied
clinical datasets are limited. In this work, we develop
statistical methodologies to characterize drug interac-
tions directly from clinical data. Specifically, we study
the response rates of single drug and drug combinations
tested in Phase II clinical trials for their anticancer activ-
ity. Our main goal is to uncover general patterns that
could inform future approaches aiming to identify effect-
ive drug combinations for anticancer treatment.
Methods
Study design
To test our statistical methodology, on May 7, 2010, we
searched PubMed with the following search key: cancer
phase II clinical trial overall response rate. From the list
of returned abstracts we selected in order of appearance
the first 1,000 clinical trials. This number was chosen to
balance the effort of manually extracting the required
data from the PubMed abstracts and the desire to include
as many trials as possible. Following an initial assessment
of our methodology with that subset of clinical trials, on
August 9, 2011, we searched PubMed again to extract
new reports between this date and the previous search.
This resulted 163 additional trials adding to a total of
1,163 trials. The reason for the latter search was to allow
us to investigate more recent trends. We did not found
any significant differences from the analysis of the initial
set of 1,000 trials and the final set of 1,163 trials. The
complete list of trials is reported in the Additional file 1.
Our primary measure for treatment success was the clin-
ical overall response rate (ORR), defined as the percent-
age of patients whose cancer shrinks (partial response) or
disappears (complete response) after treatment. Recog-
nizing the limitations of comparing response rates for
each cancer type across separate trials, we chose the
overall response rate as the main outcome measure. This
choice was based on the assumption that most phase II
trials used standard RECIST response criteria, and were
powered for a clinically relevant response rate that could
lead to a “go no-go” decision for a phase III study. Over-
all, 184 agents were tested as single agents or in combin-
ation in the collected trials.
Observed ORR
Each clinical trial reports the number of patients with an
overall response (n) and the trial sample size (N). For a
given combination tested in a given trial, n is modeled
as a random variable following the binomial distributionP njN ; pð Þ ¼ N
n
 
pn 1−pð ÞN−n , where p is an unknown
parameter representing the probability that a patient
manifest a partial or complete response to the treatment.
The Bayesian posterior distribution of p is given by a
beta distribution P pjn;Nð Þ ¼ 1B α;βð Þ pα−1 1−pð Þβ−1 , where
α=n and β=N-n and B(α,β) is the beta function
(Additional file 2). For a given combination tested in
multiple trials, we take into account that p may be dif-
ferent due to the use of different dose, schedule or can-
cer subtype on each trial. To account for these
differences, we constructed a statistical methodology
that models the existence of multiple classes of trials
(among those testing the same combination) with differ-
ent values of p (Additional file 2). In our dataset, there
were 166 combinations tested in two or more trials.
When pooling the clinical trials by the combination
tested, in 142 of these combinations the data indicates
that all trials are statistically equivalent as determined by
the Bayesian method. In these cases we pooled together
the data from clinical trials testing the same combin-
ation even though some were conducted in different
cancer subtypes. For the remaining 24 combinations,
there are significantly different response rates depending
on the cancer type. In this latter case the Bayesian method
returns two or more groups, each containing one or more
cancer types. When each group was represented by only
one trial we removed those trials from our search of syner-
gistic/antagonistic combinations. Otherwise we removed
the trials in the group with lowest number of trials. The
excluded trials are indicated in the Additional file 3. These
trials were removed because the reported ORR was incon-
sistent with the report by trials testing the same combin-
ation in the same cancer type. When all trials are
statistically equivalent, p follows a beta distribution with
α = ∑ini and β = ∑i(Ni − ni), where the index i runs over all
trials testing the combination. The expected probability of
response rates is computed from the mean of the beta dis-
tribution mean(p) = α/(α + β) = ∑ini/∑iNi, and the associ-
ated ORR is computed as ORR0 = 100%×mean(p).Null model for combinations of two non-interacting agents
In the absence of agent interactions, the probability that a
patient responds to a treatment based on two agents equals
one minus the probability that he/she does not respond to
either treatment: qij = 1− (1 − pi)(1− pj), where pi and pj are
the response probabilities for each agent when used as a sin-
gle agent. The probabilities pi were estimated using trials
where the agents were tested as single agents. In a trial
where N patients were treated with the two agents i and j,
we expected n responses with a binomial probability distri-
bution P njN ; qij
 
¼ N
n
 
qnij 1−qij
 N−n
. We estimated the
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tain as many or more responses given a non-interacting
agents hypothesis: psynergy;ij ¼ ∑Nm¼nPðmjqij;NÞ. Similarly,
we estimated the probability that there was antagonism as
the probability to obtain as many or less responses, given a
non-interacting hypothesis: pantagonism;ij ¼ ∑nm¼0Pðmjqij;NÞ.
Finally, the expected ORR under the assumption of non-
interacting agents was defined as ORR1,ij = 100%mean(qij) =
100%[1 − (1 −mean(pi))(1 −mean(pj))]. The simulations to
test the null (non-interacting) model approach were
performed as follows. Given a sample size N, uniformingly
sampled values between 0 and 1 were generated for the
probability of response to drug 1, p1, the probability of re-
sponse to drug 2, p2, and the probability to respond to the
combination of drug 1 and 2, p12. Using the probabilities p1
and p2, the probability of response to the combination of
drug 1 and 2 in the absence of drug interactions, q12 = 1 −
(1 − p1)(1 − p2), was computed. Then, n1, n2 and n12 re-
sponses out of N attempts were generated using a binomial
model with probability of success p1, p2 and p12, respect-
ively. Using the generated number of responses, the poster-
ior means p0,1 = n1/N, p0,2 = n2/N and p0,12 = n12/N were
computed. Finally, using q0,12 = 1 − (1 − p0,1)(1 − p0,2) and
n12 as input, psynergy,12 and pantagonism,12 were computed.
This procedure was repeated 10,000,000 times. The mani-
festation of synergy/antagonism was determined by com-
paring the expected ORR as obtained from the null model
ORR1 = 100%q12 with the ORR as observed ORR0 = 100%
p12. Specifically, the probability for synergy psynergy,12 was
calculated as the fraction of times that ORR0>ORR1 and
psynergy,12≥0.05. Similarly, the probability for antagonism
psynergy,12 was calculated as the fraction of times that
ORR0<ORR1 and pantagonism,12≥0.05. To compute these
fractions we divided the [0–1] interval in bins of size 0.01.Two-agents approximation to the ORR
In the 2-agent approximation model the ORR for each
agent combination c is derived from parameters quantify-
ing the response to a single agent and the interaction be-
tween two agents. These combinations are constructed
out of Na agents. The combinations are specified using
the agent to combination matrix. sci, where sci = 1 if agent
i is part of the combination c and sci = 0 otherwise. The
parameter hi denotes the response rate to agent i when
tested as a single agent. The parameters Jij are introduced
to quantify corrections due to agent interactions. The
probability pc to respond to a combination c is written as
pc ¼ ∑Nai¼1scihi þ ∑Na−1i¼1 ∑Naj¼iþ1sciscjJ ij and the associated
overall response rate is ORRc = 100%×pc. To understand
the equation for pc, it is better to focus on the case when
the drugs do not interact. In this case pc ¼ 1−
∏Nai¼1 1−hið Þsci ¼ ∑Nai¼1scihi−∑Na−1i¼1 ∑Naj¼iþ1sciscjhihj . Therefore,in the absence of interactions the equation of pc can be
written as we postulated above with J0ij ¼ −hihj. The differ-
ence between an observed Jij and the non-interacting value
ΔJ ij ¼ J ij−J0ij is used to quantify synergy (when positive)
and antagonism (when negative). The 2-agent model can
be rewritten as pc ¼ ∑Nvm¼1Acmxm , where Nv is the number
of variables (unknown hs and Js), the xm are variables
representing the hs and Js parameters, and Acm is the vari-
able to a combination matrix (Acm = 1 if variable m ap-
pears in the equation for combination c and Acm = 0
otherwise). The variables xm were estimated by solving the
corresponding least-squares problem, with some add-
itional considerations to account for the variability in the
empirical estimates of pc (Additional file 2). The 2-agent
approximation to the ORR was given by ORR2,ij = 100%
[∑iscimean(hi) + ∑ i <jsciscjmean(Jij)].
Kolmogorov-smirnov test
The kolmogorov-smirnov test [10] was used to deter-
mine the probability that two lists of ORRs were gener-
ated from the same distribution.
Results and discussion
Statistical equivalence of trials testing the same
combination
The response rate to a combination of agents may de-
pend on the dose of each agent, the treatment schedule,
and the cancer subtype. We developed a statistical meth-
odology that determines if a set of trials testing the same
combination is statistically equivalent, or if there are tri-
als with statistically different response rates. To this end,
we developed a Bayesian method that takes into account
the variations in the estimated response rates due to fi-
nite sample sizes. This Bayesian method determines
whether the number of responses reported in a set of
clinical trials are consistent with a unique response rate,
up to variations determined by the finite sample sizes, or
whether the trials cluster in two or more groups with
statistically significant response rates. In our dataset,
there were 166 agent combinations that were tested by
two or more clinical trials. In 142 combinations the ob-
served response rates were statistically equivalent. Only
in 24 combinations there is evidence of trials with statis-
tically different response rates (Additional file 3).
We note that the observation of statistical equivalence
does not imply that the response rates do not depend on
dose or cancer type. By necessity, we made the assump-
tion that in most trials within the dataset studied, the
agent doses are standard based on standard maximal tol-
erated doses defined by prior phase I trials. Response
rates were also comparable because similar agent combi-
nations or combinations of similar drug class were usu-
ally tested in the same cancer subtype. We recognized
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selected on the basis of a companion biomarker. For ex-
ample, within the studied dataset, there were 32 trials
testing trastuzumab as a single agent or in combination.
In all cases the patients enrolled were Her2/neu+, the
target of trastuzumab. Although we assumed that within
the studied dataset the trials associated with the same
agent combination are statistically equivalent, we ac-
knowledged that in some instances the results that fol-
low are biased towards specific cancer subtypes. For
example, all the interactions with trastuzumab are rele-
vant in the context of Her2/neu+patients and interac-
tions with radiation are relevant in the context of
localized disease. These biases will be reported when
necessary.
Trends as a function of the number of agents combined
The Bayesian method also reports the posterior mean of
the response rate associated with every single agent and
combination in our dataset. To investigate trends as a func-
tion of the number of agents tested, we stratified the combi-
nations by the number of agents tested. For a given number
of agents, we collected the posterior mean response rates of
all combinations testing that many agents. From this list we
determined the median and the lower and upper bound for
the 90% confidence interval, as the combination with pos-
terior response rate higher/lower than 50%/50%, 5%/95%
and 95%/5% of the samples, respectively. We observed that
the median over the posterior mean ORRs increased with
increasing the number of agents in the combination
(Figure 1). For single agents, the median ORR was below
30% and increased to above 70% for treatments with five or
more agents. Similar trends were observed when restrictingFigure 1 The ORR increases with increasing the number of
agents in the treatment. The ORR as a function of the number of
agents in the combination. The symbols represent the median
across all trials testing that many agents and the bars the 90%
confidence intervals. The 90% confidence intervals for the
combinations tested in breast cancer and those using monoclonal
antibodies have been omitted to avoid confusion.the analysis to trials in breast cancer (171 clinical trials), in-
dicating that these observations hold for specific cancer
subtypes as well. The ORR 90% confidence interval for
combinations testing a given number of agents was quite
broad. Therefore, not all combinations testing more agents
outperformed those testing lesser agents.
Targeted vs non-targeted therapies
Among the 514 combinations tested, 85 included novel
monoclonal antibodies, allowing us to test whether
targeted therapies are improving response rates. As
expected, based on prior randomized trials, the distribu-
tion of posterior mean ORRs for trials testing monoclo-
nal antibodies was shifted toward higher ORRs relative
to the distribution for trials not including monoclonal
antibodies (54% vs 46%, p-value of 0.0042 based on a
Kolmogorov-Smirnov test). Furthermore, the median
over posterior ORRs was higher for combinations in-
cluding monoclonal antibodies independently of the
number of agents in the combination (Figure 1), with
the exception of combinations with four agents.
Clinical synergy
We then focused on agent combinations resulting in tri-
als with ORRs that were significantly different than what
expected from a null model with no interactions be-
tween the agents tested. From the clinical point of view,
a combination was deemed synergistic when its ORR
was significantly higher than what was expected from
the null model of non-interacting agents, and antagonis-
tic when significantly lower. The null model for non-
interacting drug combinations is mathematically de-
scribed in the methods section. In simple words, in the
absence of drug interactions the probability that a pa-
tient responds to a two-drug combination is equal to the
probability that he/she responds to at least one drug in
the combination. The probability that a patient responds
to at least one drug in the combination can be estimated
using as input the trials testing the drugs as single
agents. Once we have an estimate of the probability that
a patient responds to the two-drug combination in the
absence of interactions, we can determine the probabil-
ity to observe as many or more responses in a trial with
a given sample size (psynergy), the probability to observe
as many or less responses (pantagonism) and the expected
response rate in the absence of drug interactions ORR1.
The ability of this approach to uncover synergistic/an-
tagonistic interactions will depend on the sample sizes
and the degree of synergy/antagonism. This is illustrated
in Figure 2a-c for simulated data with sample sizes 100,
500 and 1,000. The red areas highlight the region where
the number of observed responses is consistent with the
null model of non-interacting agent. In turn, the white
areas represent cases where our approach correctly
Figure 2 Clinical synergy and antagosnism. The observed ORRs (ORR0) as a function of the expected ORR assuming there are no agent-agent
interactions (ORR1). Panels a)-c) show results obtained from the simulation of clinical trials with the reported sample sizes (see Methods). The red
color intensity is proportional to fraction of times that a two-agent combination with the corresponding observed ORR0 and expected ORR1 is
dimmed non-interacting. d) The results obtained for the two-agent combinations in the clinical data. The diagonal line represents the perfect
agreement between the two. Circles represent combinations with evidence for synergy (psynergy < 0.05), squares represent combinations with
evidence for antagonism (pantagonism < 0.05), and the pluses represent combinations without evidence for synergy or antagonism (psynergy≥0.05
and pantagonism≥0.05).
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ergistic or antagonistic. As expected, our ability to dis-
criminate from the null model increases as the sample
size increases. Of course, in addition to the statistical
significance for synergy/antagonism we should focus on
the effect size, i.e. how much the observed response rate
(ORR0) deviates from what expected from the null
model for non-interacting drugs (ORR1).
Figure 2d shows the classification of the two-agent
combinations in our dataset into synergistic (psynergy <
0.05), antagonistic (pantagonism < 0.05) or non-interacting
(psynergy≥0.05 and pantagonism≥0.05). Table 1 and 2 report
the two-agent combinations with evidence for synergy
and antagonism, respectively. About half of the predicted
synergistic combinations are the standard of care in spe-
cific cancer types (e.g., docetaxel+doxorubicin in breast
cancer), indicating that our analysis captures the current
trends in cancer treatment (Table 1). The remaining syn-
ergistic combinations should be further studied to evalu-
ate their potential to improve cancer treatment. In
contrast, only one antagonistic drug combinations is
currently used as standard of care for the corresponding
cancer subtypes (Table 2).
We tested the hypothesis that synergy was more com-
mon in combinations using monoclonal antibodies, a
class of targeted therapies. However, only 1 out 15combinations in the list of synergistic 2-agent combina-
tions included at least one monoclonal antibody (Table 1,
rituximab+alpha-interferon). Although a small sample
size, requiring future validation, these data support a
lack of significant enrichment of synergy by the addition
of a monoclonal antibody relative to other agent combi-
nations (p-value = 0.99, Fischer’s exact test). This obser-
vation may also indicate that synergy is as common
between chemotherapeutic agents as between a chemo-
therapeutic agent and a monoclonal antibody.
Quantifying agent interactions using a 2-agent
approximation
Understanding that the analysis assessing clinical syn-
ergy is limited by the availability of clinical trials testing
each agent as a single agent and the two agents in com-
bination, we performed a 2-agent approximation. A new
agent is often added to an existing regimen that already
includes two or more agents, without testing the new
agent in combination with each agent within the existing
regimen. Therefore, we estimated the response rate of a
combination of two agents from a collection of trials
where these agents appeared as part of a combination
with more than two agents. We developed a model for
the ORR as a function of parameters characterizing the
single agent and 2-agent responses (see Methods). A
Table 1 Synergistic 2-agent combinations
Agent 1 Agent 2 Standard of care* Expected ORR1 Observed ORR0 psynergy Cancer subtype
Docetaxel Doxorubicin Yes 40 65 7.70E-43 Breast cancer
Oxaliplatin 5-fluorouracil Yes 25 52 1.82E-17 Colorectal, gastric cancer
Irinotecan Etoposide No 19 66 4.98E-13 Lung cancer
Doxorubicin Ifosfamide Yes 19 48 1.20E-09 Gynecologic, soft tissue sarcoma
Bortezomib Thalidomide Yes 56 100 2.13E-09 Myeloma
Capecitabine Irinotecan No 35 48 9.53E-09 Colorectal, gastric, lung cancer
S-1 Irinotecan No 33 47 1.20E-07 Colorectal, gastric, lung cancer
Oxaliplatin Doxorubicin No 27 68 1.30E-07 Ovarian cancer
Oxaliplatin Irinotecan Yes 24 52 4.30E-06 Colorectal, lung cancer
Capecitabine Radiation No 65 88 3.11E-05 Cervical cancer
Rituximab Alpha-interferon No 67 94 2.48E-04 Lymphoma
Oxaliplatin Capecitabine Yes 38 44 3.41E-03 Colorectal, gastric cancer
5-fluorouracil Irinotecan Yes 22 38 5.87E-03 Colorectal cancer
Capecitabine Alpha-interferon No 38 54 3.34E-02 Renal cancer
Fludarabine Thalidomide No 78 100 4.05E-02 Leukemia
*By National Comprehensive Cancer Network (NCCN) guidelines.
The combinations with an observed ORR (ORR0) that is significantly higher than the expected ORR in the absence of agent interactions (ORR1).
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evaluate the performance of the 2-agents approximation.
For each combination, the empirically estimated ORR
was removed from the dataset and then estimated using
the 2-agent approximation. Figure 3 shows a scatter plotTable 2 Antagonistic 2-agents combinations
Agent 1 Agent 2 Standard of care* Expected OR
Docetaxel Topotecan No 42
Bortezomib Rituximab No 78
Temozolomide Alpha-interferon No 38
Capecitabine Bortezomib No 58
Fludarabine Alemtuzumab No 83
Bevacizumab Temozolomide No 48
Capecitabine Trimetrexate No 45
Docetaxel Irinotecan No 37
Bortezomib Temsirolimus No 64
Temozolomide Interleukin-2 No 49
Docetaxel Gefitinib No 71
Docetaxel 5-fluorouracil No 38
Rituximab Temsirolimus No 75
Temozolomide Radiation No 64
Fludarabine Alpha-interferon No 76
G-CSF Rituximab No 71
Doxorubicin Bevacizumab No 40
Docetaxel Imatinib No 46
Docetaxel Capecitabine Yes 49
Vinorelbine Mitoxantrone No 42
*By National Comprehensive Cancer Network (NCCN) guidelines.
The combinations with an observed ORR (ORR0) that is significantly lower than theof the mean ORR as predicted by the 2-agent approxi-
mation (ORR2) as a function of the mean ORR empirical
estimates (ORR0). We noticed that in most cases the
predicted ORRs were lower than the empirical estimates,
as can be deduced from the higher density of points inR1 Observed ORR2 pantagonism Cancer subtype
12 2.94E-11 Lung, ovarian cancer
53 1.20E-09 Lymphoma
18 5.87E-08 Melanoma
14 9.02E-08 Breast cancer
64 1.27E-07 CLL, leukemia
16 1.41E-07 Melanoma
6 2.15E-06 Colorectal cancer
18 1.15E-05 Gastric, lung, ovarian cancer
30 1.25E-05 Myeloma
16 1.97E-05 Melanoma
31 2.29E-05 Lung cancer
25 1.71E-04 Gastric, head and neck cancer
59 2.44E-03 Lymphoma
46 2.51E-03 Breast cancer
52 2.55E-03 Lymphoma
61 4.69E-03 CLL, lymphoma
21 9.11E-03 Breast cancer
28 2.09E-02 Breast cancer
43 4.48E-02 Breast, gastric cancer
29 4.62E-02 Breast cancer
expected ORR in the absence of agent interactions (ORR1).
Figure 3 Performance of the 2-agents approximation. Scatter
plot of the empirically estimated ORR (ORR0) as a function the leave-
one-out crossvalidation prediction based on the 2-agent
approximation (ORR2). Circles represent combinations using one
agent, squares combinations using two agents and pluses
combinations using three or more agents.
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and 69% of the combinations with 1, 2 and 3 or more
agents, respectively, the predicted ORR was lower than
the empirical estimate (ORR2<ORR0). Therefore, the 2-
agent approximation can be used to estimate a lower
bound to the ORR. More precisely, with about 75% con-
fidence, the actual ORR is higher than what predicted by
the 2-agent approximation. In practical terms this means
that when the 2-agent approximation predicts a high
ORR, with about 75% confidence we should expect as
high or higher responses rates. On the other hand, if the
2-agent approximation predicts a low ORR, the predic-
tion become less informative, since likely the ORR will
actually be higher. Using the 2-agent approximation we
estimated the ORR of all 2-agent combinations, provided
that the two agents appeared together in at least one
trial within our dataset (Additional file 4). We noted
again that these predictions were likely underestimating
the actual ORR. We also noted that these predictions
were subject to the same biases discussed above. If an
agent has been tested in a specific cancer subtype, then
the predicted ORRs for combinations using that agent
are expected to be valid within that subtype.
Conclusions
Statistical and systems biology methodologies have been
proposed for the rational discovery of combinatorial ther-
apies [2]. Our ability to test the performance of these
methodologies is limited, however, by the availability of a
catalog of synergistic drug combinations. Similarly, a cata-
log of drugs with antagonistic interactions could help to
design statistical and systems biology methodologies toanticipate adverse drug interactions [8]. We propose the
pooled analysis of Phase II clinical trials as a methodology
to develop a catalog of synergistic and antagonistic drug
combinations. This catalog can be used as a gold standard
for testing methodologies attempting to infer the interac-
tions between drugs in the treatment of cancer. Here we
provide a preliminary version of this catalog, derived from
the analysis of 1,163 clinical trials and 53,745 subjects. The
synergistic 2-agent combinations are reported in Table 1
and the antagonistic two-agent combinations in Table 2.
The pooled analysis of this data supports the hypoth-
esis that the ORR increases with increasing the number
of drugs used in combination, from 25% for single
agents to about 85% for five drugs combinations. In
most cases, this increase is explained by the additive ef-
fect of the drugs in the combination. However, for cer-
tain combinations, the ORRs are significantly greater
than what would be expected from the additive effects
of the two drugs, which represent our predicted syner-
gistic drug combinations. On the other hand, there were
also drug combinations with ORRs significantly below
what is expected from their additive effects, which repre-
sent antagonistic drug combinations.
To evaluate the impact of targeted therapies, we fo-
cused on monoclonal antibodies. We recognize that
there are many different and emerging targeted therapies
such as kinase inhibitors. However, monoclonal anti-
bodies were the only class present in a sufficient number
to conduct the analysis. We observe a significant 8% in-
crease in the average ORR of trials using monoclonal
antibodies, indicating that these targeted therapies are
indeed improving the response rates. However, among
the reported synergistic combinations, there was not a
significant enrichment of combinations using monoclo-
nal antibodies. Based on this evidence, we conclude that
synergy is as common between chemotherapeutic agents
as between a chemotherapeutic agent and a monoclonal
antibody. These methodologies will be more important
as ongoing studies are now assessing more combinations
of targeted agents with standard chemotherapy as well
as combinations of targeted agents.
Using a 2-agent approximation we estimated the ORR
of all combinations of two agents, provided the two
agents were tested together, alone or in combination
with other agents, in at least one clinical trial. A cross-
validation analysis revealed that this 2-agent approxima-
tion provides a good lower bound estimate of the ORR.
In practical terms, this means that the combinations
with predicted high ORRs are quite likely to manifest
high ORRs, but if the ORR is predicted to be low, then
the prediction is not informative. The 2-agent approxi-
mation predictions, reported in the Additional file 4, can
be used as a reference to prioritize further testing of
combination therapy for cancer treatment.
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ition assays [9] does not necessarily predicts clinical synergy,
because of drug metabolism or other factors. For example,
an in vitro study using breast cancer cell lines, it was
reported that the combination docetaxel+doxorubicin was
antagonistic, while the combination docetaxel+epirubicin
was synergistic [11]. In contrast, we found that the combin-
ation docetaxel+doxurubicin was synergistic based on the
Phase II trials clinical data of breast cancer, while the com-
bination of docetaxel+epirubicin was antagonistic, albeit in
lung cancer. This example emphasizes that in vitro evidence
for synergy, while potentially informative, should not be the
gold standard, underscoring the need for gold standards of
synergy in the clinical context.
In a more general perspective, this analysis opens the
question of whether we should test both new treatments
and the standard of care on each trial, or whether we
should test only the new treatments in new trials and
compare the results against the gold standard library.
This may be particularly relevant to efforts to improve
trial efficiency in order to test multiple targeted new
agents in combination. Clearly, given the ORR of a new
treatment, we can provide estimates of clinical benefit
and synergy using our methodology. Looking ahead, the
statistical methodology developed in this work can be
further tested and validated with expanded phase II clin-
ical trial data sets, more specific data sets, and in pro-
spective predictions of new combinations moving into
phase II studies.
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